Head-To-Head Comparison: Zura Bio (NASDAQ:ZURA) and Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH) and Zura Bio (NASDAQ:ZURA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Analyst Ratings

This is a summary of current ratings and target prices for Dianthus Therapeutics and Zura Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1	0	12	1	2.93
Zura Bio	1	0	5	1	2.86

Dianthus Therapeutics currently has a consensus price target of $124.27, indicating a potential upside of 11.86%. Zura Bio has a consensus price target of $17.00, indicating a potential upside of 190.60%. Given Zura Bio’s higher possible upside, analysts clearly believe Zura Bio is more favorable than Dianthus Therapeutics.

Institutional & Insider Ownership

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 12.4% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Dianthus Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500.

Profitability

This table compares Dianthus Therapeutics and Zura Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Zura Bio	N/A	-56.13%	-50.15%

Valuation and Earnings

This table compares Dianthus Therapeutics and Zura Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.90 million	3,189.81	-$162.34 million	($4.15)	-26.77
Zura Bio	N/A	N/A	-$99.35 million	($1.13)	-5.18

Zura Bio has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Zura Bio beats Dianthus Therapeutics on 7 of the 13 factors compared between the two stocks.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.